Skye Bioscience, Inc. — Director's Dealing 2020

Aug 12, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Emerald Bioscience, Inc. (EMBI)
CIK: 0001516551
Period of Report: 2020-08-07

Reporting Person: DALESANDRO MARGARET (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-08-07	Director Option Grant (Right to Buy)	$0.045	A	250000	Acquired	2030-08-07	Common Stock (250000)	Direct

Footnotes

F1: Each of the Options shall be exercisable for a price of $0.045 per Option Share for ten years from August 7, 2020 (the "Grant Date") and all
Options will vest 10% on the Grant Date and 90% in equal semiannual installments over two years.